- Open Access
Inhalation of the Rho-kinase inhibitor Y-27632 reverses allergen-induced airway hyperresponsiveness after the early and late asthmatic reaction
Respiratory Research volume 7, Article number: 121 (2006)
In guinea pigs, we have previously demonstrated that the contribution of Rho-kinase to airway responsiveness in vivo and ex vivo is enhanced after active sensitization with ovalbumin (OA). Using conscious, unrestrained OA-sensitized guina pigs, we now investigated the role of Rho-kinase in the development of airway hyperresponsiveness (AHR) after the allergen-induced early (EAR) and late asthmatic reaction (LAR) in vivo.
Histamine and PGF2α PC100-values (provocation concentrations causing 100% increase in pleural pressure) were assessed before OA-challenge (basal airway responsiveness) and after the OA-induced EAR (5 h after challenge) and LAR (23 h after challenge). Thirty minutes later, saline or the specific Rho-kinase inhibitor Y-27632 (5 mM, nebulizer concentration) were nebulized, after which PC100-values were reassessed.
In contrast to saline, Y-27632 inhalation significantly decreased the basal responsiveness toward histamine and PGF2α before OA-challenge, as indicated by increased PC100 -values. Both after the allergen-induced EAR and LAR, AHR to histamine and PGF2α was present, which was reversed by Y-27632 inhalation. Moreover, there was an increased effectiveness of Y-27632 to reduce airway responsiveness to histamine and PGF2α after the EAR and LAR as compared to pre-challenge conditions. Saline inhalations did not affect histamine or PGF2α PC100-values at all. Interestingly, under all conditions Y-27632 was significantly more effective in reducing airway responsiveness to PGF2α as compared to histamine. Also, there was a clear tendency (P = 0.08) to a more pronounced degree of AHR after the EAR for PGF2α than for histamine.
The results indicate that inhalation of the Rho-kinase inhibitor Y-27632 causes a considerable bronchoprotection to both histamine and PGF2α. Moreover, the results are indicative of a differential involvement of Rho-kinase in the agonist-induced airway obstruction in vivo. Increased Rho-kinase activity contributes to the allergen-induced AHR to histamine and PGF2α after both the EAR and the LAR, which is effectively reversed by inhalation of Y-27632. Therefore, Rho-kinase can be considered as a potential pharmacotherapeutical target in allergic asthma.
Asthma is an inflammatory airways disease characterized by airway hyperresponsiveness (AHR) to a variety of stimuli, including contractile agonists such as histamine and prostaglandin F2α (PGF2α) [1–4].
Agonist-induced smooth muscle contraction is largely governed by phosphorylation of the 20kDa myosin light chain (MLC20) . MLC20 phosphorylation is initiated by an increase in intracellular Ca2+-concentration ([Ca2+]i) and subsequent formation of Ca2+-calmodulin, resulting in activation of myosin light chain kinase (MLCK). The extent of MLC20 phosphorylation is determined by the balance between MLCK and myosin light chain phosphatase (MLCP) activities . Recently, it has been established that contractile stimuli do not exert their effects only by increasing [Ca2+]i, but also by increasing the sensitivity of the contractile apparatus to Ca2+. One of the main pathways involved in this Ca2+-sensitization is the RhoA/Rho-kinase pathway [7, 6]. Activated Rho-kinase interferes with the equilibrium of MLCK and MLCP activities by phosphorylating and thereby inactivating the myosin binding subunit of MLCP. This leads to an augmentation of MLC20 phosphorylation and hence an elevated level of contraction at an established [Ca2+]i [7, 8].
In vitro studies have indicated a receptor-dependent role of Rho-kinase in agonist-induced airway smooth muscle (ASM) contraction. Thus, the potency and maximal effect of histamine-induced contraction of guinea pig tracheal smooth muscle preparations were unaffected by inhibition of Rho-kinase, whereas these parameters were strongly dependent on Rho-kinase for PGF2α-induced contraction . Growth factor-induced contraction of human and guinea pig ASM preparations appeared to be almost completely dependent on Rho-kinase [10, 11]. presumably via generation of contractile prostaglandins . Thusfar, no reports have been published on a differential role for Rho-kinase in airway responsiveneness to contractile agonists in vivo.
Recently, Rho-kinase has emerged to be a potential target in airways diseases, including allergic asthma . Ex vivo, it has been demonstrated that Rho/Rho-kinase-mediated Ca2+-sensitization is enhanced in acetylcholine-induced contraction of bronchial smooth muscle obtained from repeatedly allergen-challenged rats . Moreover, we have recently demonstrated that active allergic sensitization (without subsequent allergen exposure) increased contractile potency of guinea pig tracheal smooth muscle preparations towards histamine and PGF2α in a Rho-kinase dependent fashion. Similarly, passive sensitization-induced nonspecific ASM hyperresponsiveness and specific allergen responsiveness in these preparations were found to be dependent on Rho-kinase as well . Also in vivo, using permanently instrumented, unanaesthetized, unrestrained guinea pigs, we found that the contribution of Rho-kinase to airway responsiveness to histamine was augmented after active allergic sensitization . However, the contribution of Rho-kinase to the development of AHR after the allergen-induced early (EAR) and late (LAR) asthmatic reaction in this model is presently unknown.
In the present study, using the same model, we therefore investigated the involvement of Rho-kinase in the airway responsiveneness to histamine and PGF2α before and after the allergen-induced EAR and LAR. We demonstrate that there is a differential role of Rho-kinase in the agonist-induced airway obstructions and that inhalation of the specific Rho-kinase inhibitorY-27632 results in a strong bronchoprotection to both agonists Moreover, the results indicate that increased Rho-kinase activity contributes to allergen-induced AHR to histamine and PGF2α after both the EAR and the LAR, which is effectively reversed by Y-27632 inhalation.
Outbred specified pathogen-free male Dunkin Hartley guinea pigs (Harlan, Heathfield, U.K.), weighing 500–700 g, were used in this study. The animals were actively IgE-sensitized to ovalbumin (OA) as described previously . In short, 0.5 ml of an allergen solution containing 100 μg/ml OA and 100 mg/ml Al(OH)3 in saline was injected intraperitoneally, while another 0.5 ml was divided over seven intracutaneous injection sites in the proximity of lymph nodes in the paws, lumbar regions and the neck. The animals were operated 2 weeks after sensitization and used experimentally in weeks 4 to 8 after sensitization. The animals were group-housed in individual cages in climate controlled animal quarters and given water and food ad libitum, while a 12-h on/12-h off light cycle was maintained. All protocols described in this study were approved by the University of Groningen Committee for Animal Experimentation.
Measurement of airway function
Airway function was assessed in conscious, permanently instrumented, unrestrained guinea pigs, by on-line measurement of pleural pressure (Ppl) as described previously . In short, a small saline-filled balloon-catheter was surgically implanted inside the thoracic cavity. The free end of the catheter was driven subcutaneously to the neck of the animal, where it was exposed and attached permanently. Via an external saline-filled canula the pleural balloon was connected to a pressure transducer (Ohmeda DTX, SpectraMed, Bilthoven, the Netherlands) and an on-line computer system, enabling continuous measurement of Ppl changes (in cm H2O). We have previously found that changes in Ppl are linearly correlated with changes in airway resistance and hence can be used as a sensitive index for bronchoconstriction .
Provocations with OA, histamine and PGF2α, as well as administration of Y-27632 were performed by inhalation of aerosolized solutions. Aerosols were produced by a DeVilbiss nebulizer (type 646; DeVilbiss, Somerset, PA, USA), driven by an airflow of 8 l/min and resulting in an output of 0.33 ml/min. Provocations were carried out in a perspex cage (internal volume of 9 l) in which the guinea pigs could move freely . Before the start of the experiment, the animals were habituated to the experimental conditions on two sequential days at least one week after surgery, when preoperative weight had been restored. On the first day, the animals were placed in the provocation cage unconnected to the pressure transducer. After an adaptation period of at least 30 min, three consecutive provocations with saline were performed, each exposure lasting 3 min and separated by a 7-min interval. The next day, this procedure was repeated with the animals connected to the measurement system.
On the experimental days, following the habituation procedure, OA, histamine and PGF2α provocations were performed as described below. All provocations were preceded by an adaptation period of at least 30 min, followed by two consecutive control provocations with saline as described above. Baseline Ppl was calculated by averaging the Ppl of the last 20 min of the adaptation period.
To assess the airway reactivity to histamine, provocations were performed with an initial 25 μg/ml histamine solution in saline, followed by increasing dosage steps of 25 μg/ml. Histamine provocations lasted 3 min, separated by 7 min intervals. Animals were challenged until Ppl was increased by more than 100 % above baseline for at least 3 consecutive minutes. Ppl returned to baseline value within 15 min after the last provocation. The provocation concentration causing a 100 % increase of Ppl (PC100-value) was derived by linear intrapolation of the concentration-Ppl curve and was used as a measure for airway reactivity toward the agonist. Using the same procedure, airway reactivity to PGF2α was determined by using increasing concentrations of 1.25, 2.5, 5, 10, 15, 20, 37.5, 50, 75, 100 and 125 μg/ml of PGF2α in saline, respectively. OA-provocations were performed by inhalation of increasing aerosol concentrations of 0.5 and 1.0 mg/ml OA in saline for 3 min, separated by 7 min intervals. Allergen inhalations were discontinued when an increase in Ppl of more than 100 % was observed. Using these conditions, none of the animals developed anaphylactic shock after allergen provocation.
On two different occasions, separated by a one week interval, histamine or PGF2α PC100-values were assessed 24 h before OA-challenge, and at 5 h and 23 h after the OA-challenge, i.e. after the early (EAR) and late (LAR) asthmatic reaction, respectively. Thirty minutes after each histamine or PGF2α inhalation, saline or Y-27632 (5 mM) was nebulized during 3 min, followed by reassessment of the histamine or PGF2α PC100-values 30 min later. Saline and Y-27632 inhalations were alternated using a random crossover design.
All data represent means ± s.e. mean from n separate experiments. Statistical significance of differences was evaluated using a repeated measures one way analysis of variance (ANOVA) followed by a Holm-Sidak post-test, and significance was accepted when P < 0.05.
Ovalbumin (grade III) and histamine dihydrochloride were obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.). PGF2α was obtained from Pharmacia and Upjohn (Puurs, Belgium) and (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexane carboxamide (Y-27632) was obtained from Tocris Cookson Ltd. (Bristol, U.K.). All other chemicals were of analytical grade.
In contrast to saline (Fig. 1A), Y-27632 significantly decreased the basal responsiveness toward histamine before OA-challenge, as indicated by an increased PC100 (Fig. 1B). After the EAR, AHR had developed (Fig. 1A and 1B), which was reversed by Y-27632 to the level of basal responsiveness in the absence of the Rho-kinase inhibitor (Fig. 1B). Interestingly, the AHR after the LAR was even fully reversed to the basal responsiveness in the presence of Y-27632 (Fig. 1B). Saline inhalations did not affect histamine PC100-values after the EAR and LAR (Fig. 1A).
As shown in figure 2B, basal responsiveness to PGF2α was also significantly inhibited by Y-27632 inhalation to a considerable extent. The AHR after the EAR was strongly reversed by Y-27632 inhalation to a hyporesponsive level as compared to basal airway responsiveness in the absence of the Rho-kinase inhibitor (P < 0.05). As for histamine, Y-27632 inhalation fully reversed the AHR to PGF2α after the LAR to the basal responsiveness as measured in the presence of Y-27632 (Fig. 2B). As with histamine, saline inhalations did not affect PC100 values for PGF2α (Fig. 2A).
As compared to basal conditions (1.7 ± 0.1-fold decrease of airway responsiveness), the effectiveness of Y-27632 to reduce the airway responsiveness to histamine after the EAR (3.3 ± 0.4-fold) and after the LAR (2.3 ± 0.1-fold) was significantly increased (P < 0.05 both; Fig. 3A). Also for PGF2α, Y-27632 inhalation was much more effective in reducing the airway responsiveness after the EAR (7.3 ± 1.1-fold, P < 0.05) and the LAR (5.6 ± 0.7-fold, P < 0.05) as compared to pre-challenge conditions (3.8 ± 0.5-fold decrease, Fig. 3B). Interestingly, under all conditions Y-27632 was significantly more effective in reducing airway responsiveness to PGF2α as compared to histamine, indicating that there is a receptor-dependent role for Rho-kinase in airway responsiveness in vivo. In addition, we found that there is a clear tendency (P = 0.08) for a more pronounced degree of AHR after the EAR for PGF2α (5.8 ± 1.1-fold increase in airway reactivity) than for histamine (3.3 ± 0.4-fold increase in airway reactivity). No difference was observed in the degree of AHR after the LAR for both agonists (1.7 ± 0.2 and 1.6 ± 0.2 for PGF2α and histamine, respectively).
In the present study, we demonstrated that inhalation of the Rho-kinase inhibitor Y-27632 causes a considerable bronchoprotection against histamine and PGF2α under basal conditions. Moreover, we showed for the first time that in conscious, freely moving, actively OA-sensitized guinea pigs, inhalation of the Rho-kinase inhibitor Y-27632 reverses the AHR to both agonists after the allergen-induced EAR and LAR. The results strongly indicate that an increased Rho-kinase activity is involved in the development of the allergen challenge-induced AHR, as demonstrated by an enhanced effectiveness of Y-27632 to inhibit the increased airway responsiveness to histamine and PGF2α, both after the EAR and the LAR.
Further investigations are warranted to reveal the exact mechanisms underlying the increased contribution of Rho-kinase to airway responsiveness after the EAR and LAR. Evidence exists that allergic sensitization by itself is already a key process in augmenting the role of Rho-kinase in contractile airway responsiveness. Thus, we previously found that active allergic sensitization by itself, without subsequent allergen exposure, is sufficient to induce an enhanced role of Rho-kinase in guinea pig airway smooth muscle contraction ex vivo and airway responsiveness in vivo . Also in passively sensitized guinea pig tracheal preparations, we recently found that the nonspecific hyperresponsiveness in response to histamine and methacholine was fully normalized by Rho-kinase inhibition . The enhanced contribution of Rho-kinase to airway responsiveness could involve increased expression of RhoA, as protein levels of this upstream activator of Rho-kinase have been reported elevated both after allergic sensitization in guinea pigs  and after repeated allergen challenge in rats  and mice . Inflammatory cells – activated during the allergic reaction – release mediators, including prostaglandins, leukotrienes and growth factors [18, 19], which have been reported to be dependent on Rho-kinase for their contractile effects [10, 11]. It can be envisaged that there is synergism in Rho-kinase activation between such mediators and the inhaled agonists, which results in a higher efficacy of Rho-kinase inhibition. In addition, Rho-kinase inhibition might have effects on airway inflammation itself, as has been suggested in a murine model of acute allergic airway inflammation. In anaesthetized mice, it was found that when Y-27632 was given intranasally prior to allergen challenge, pulmonary eosinophilia was reduced, as shown by a decreased number of eosinophils in the bronchoalveolar lavage (BAL) fluid . In the same study, it was also demonstrated that intranasally administered Y-27632, which was given before every allergen challenge, reduced the repeated allergen-induced increased responsiveness to intravenously applied methacholine, which might be correlated to effects on airways inflammation . Also, it has been demonstrated in vitro that Y-27632 decreased the release of the Th2 cytokines IL-4 and IL-5 .
It has been previously reported that a differential contribution of Rho-kinase to histamine- and PGF2α-induced ASM contraction exists in vitro . Fully in line with those findings, we found that such a differential role of Rho-kinase also exists in vivo. Thus, under all conditions inhalation of Y-27632 was significantly more effective in reducing airway responsiveness to PGF2α as compared to histamine. Moreover, there was a strong tendency to a more pronounced AHR after the EAR in response to PGF2α as compared to histamine. Together with the higher efficacy by which Y-27632 inhalation reduces airway responsiveness to PGF2α as compared to histamine, this might suggest that the severity of AHR to a certain agonist is associated with the extent to which the agonist is dependent on Rho-kinase for its contractile effect.
Inhalation of the Rho-kinase inhibitor Y-27632 causes a considerable bronchoprotection to histamine and PGF2α. Moreover, a differential involvement of Rho-kinase in the contractile agonist-induced airway obstructions exists in vivo. Increased Rho-kinase activity contributes to the allergen-induced AHR to histamine and PGF2α after both the EAR and the LAR, which is effectively reversed by inhalation of Y-27632. Therefore, Rho-kinase can be considered as a potential pharmacotherapeutical target in allergic asthma.
airway smooth muscle;
early asthmatic reaction;
late asthmatic reaction;
myosin light chain;
- PC100 :
provocation concentration causing 100 % increase in pleural pressure;
- Ppl :
- PGF2α :
Hargreave FE, O'Byrne PM, Ramsdale EH: Mediators, airway responsiveness, and asthma. J Allergy Clin Immunol 1985, 76:272–276.
Durham SR, Craddock CF, Cookson WO, Benson MK: Increases in airway responsiveness to histamine precede allergen-induced late asthmatic responses. J Allergy Clin Immunol 1988, 82:764–770.
Cockcroft DW: Nonallergic airway responsiveness. J Allergy Clin Immunol 1988, 81:111–119.
Kharitonov SA, Sapienza MA, Barnes PJ, Chung KF: Prostaglandins E2 and F2alpha reduce exhaled nitric oxide in normal and asthmatic subjects irrespective of airway caliber changes. Am J Respir Crit Care Med 1998, 158:1374–1378.
Pfitzer G: Invited review: regulation of myosin phosphorylation in smooth muscle. J Appl Physiol 2001, 91:497–503.
Somlyo AP, Somlyo AV: Ca2+ Sensitivity of Smooth Muscle and Nonmuscle Myosin II: Modulated by G Proteins, Kinases, and Myosin Phosphatase. Physiol Rev 2003, 83:1325–1358.
Fukata Y, Amano M, Kaibuchi K: Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001, 22:32–39.
Wettschureck N, Offermanns S: Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med 2002, 80:629–638.
Schaafsma D, Gosens R, Bos IS, Meurs H, Zaagsma J, Nelemans SA: Allergic sensitization enhances the contribution of Rho-kinase to airway smooth muscle contraction. Br J Pharmacol 2004, 143:477–484.
Gosens R, Schaafsma D, Grootte Bromhaar MM, Vrugt B, Zaagsma J, Meurs H, Nelemans SA: Growth factor-induced contraction of human bronchial smooth muscle is Rho-kinase-dependent. Eur J Pharmacol 2004, 494:73–76.
Schaafsma D, Gosens R, Bos S, Meurs H, Zaagsma J, Nelemans A: Role of contractile prostaglandins and Rho-kinase in growth factor-induced airway smooth muscle contraction. Respir Res 2005, 6:85.
Gosens R, Schaafsma D, Nelemans SA, Halayko AJ: Rho-Kinase as a Drug Target for the Treatment of Airway Hyperresponsiveness in Asthma. Mini Rev Med Chem 2006, 6:339–348.
Chiba Y, Takada Y, Miyamoto S, MitsuiSaito M, Karaki H, Misawa M: Augmented acetylcholine-induced, Rho-mediated Ca2+ sensitization of bronchial smooth muscle contraction in antigen-induced airway hyperresponsive rats. Br J Pharmacol 1999, 127:597–600.
Schaafsma D, Zuidhof AB, Nelemans SA, Zaagsma J, Meurs H: Inhibition of Rho-kinase normalizes nonspecific hyperresponsiveness in passively sensitized airway smooth muscle preparations. Eur J Pharmacol 2006, 531:145–150.
Van Amsterdam RG, Brouwer F, Zaagsma J: Analysis of the beta-adrenoceptor mediated inhibition of IgG1 and IgE dependent guinea-pig anaphylactic tracheal smooth muscle contraction. Agents Actions 1989, 26:48–51.
Santing RE, Meurs H, van der Mark TW, Remie R, Oosterom WC, Brouwer F, Zaagsma J: A novel method to assess airway function parameters in chronically instrumented, unrestrained guinea-pigs. Pulm Pharmacol 1992, 5:265–272.
Chiba Y, Ueno A, Shinozaki K, Takeyama H, Nakazawa S, Sakai H, Misawa M: Involvement of RhoA-mediated Ca2+ sensitization in antigen-induced bronchial smooth muscle hyperresponsiveness in mice. Respir Res 2005, 6:4.
McKay S, Sharma HS: Autocrine regulation of asthmatic airway inflammation: role of airway smooth muscle. Respir Res 2002, 3:11.
Sampson AP: The role of eosinophils and neutrophils in inflammation. Clin Exp Allergy 2000, 30 Suppl 1:22–27.
Henry PJ, Mann TS, Goldie RG: A Rho kinase inhibitor, Y-27632 inhibits pulmonary eosinophilia, bronchoconstriction and airways hyperresponsiveness in allergic mice. Pulm Pharmacol Ther 2005, 18:67–74.
Aihara M, Dobashi K, Iizuka K, Nakazawa T, Mori M: Comparison of effects of Y-27632 and Isoproterenol on release of cytokines from human peripheral T cells. Int Immunopharmacol 2003, 3:1619–1625.
We thank the Netherlands Asthma Foundation for financial support (grant 01.83).
The author(s) declare that they have no competing interests.
DS designed and coordinated the study, performed a major part of the experiments, performed the statistical analysis and drafted the manuscript. ISTB and ABZ substantially assisted in performing the experiments. JZ participated in the design of the study and the interpretation of results. HM supervised the study, participated in its design and in interpretation of results as well as in the preparation of the manuscript. All authors read and approved the final manuscript.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Schaafsma, D., Bos, I.S.T., Zuidhof, A.B. et al. Inhalation of the Rho-kinase inhibitor Y-27632 reverses allergen-induced airway hyperresponsiveness after the early and late asthmatic reaction. Respir Res 7, 121 (2006). https://doi.org/10.1186/1465-9921-7-121
- Airway Smooth Muscle
- Airway Responsiveness
- Myosin Light Chain Kinase
- Myosin Light Chain Phosphatase